Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/01—Hydrolysed proteins; Derivatives thereof
  • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
  • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
  • A61K9/7007—Drug-containing films, membranes or sheets
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents

Definitions

• the present invention relates to a sheet-form jelly-like preparation that contains a drug except an allergenic protein from cedar pollen and that dissolves intraorally; and a method for producing the sheet-form preparation.
• Orally available drugs in the current market are in the forms of uncoated tablets, coated tablets, capsules, powders, granules, liquid medicines, and the like. Further, intraorally disintegrating tablets and fast dissolving intraoral films are in the market as drugs disintegrated in the mouth cavity and absorbed at the digestive tract.
• one dosage form is focused on in which a drug is taken by disintegrating or dissolving the drug only with saliva and without intraorally chewing the drug; such a dosage form improves benefits of patients and caregivers. This is due to an increase in the number of patients with disability in ingestion of food and drink, in other words, those having difficulty in mastication and swallowing, involving an increase in the old people population.
• Examples of the water-containing jelly-like dosage form disclosed so far include jelly formulations containing carrageenan, locust bean gum, and polyacrylic acid or its partially neutralized product or its salt (see Patent Document 1), and pharmaceutical jelly composition containing a jelly base and an alkaline salt (see Patent Document 2).
• These jelly formulations are those containing a gelling agent thermoreversible at high temperatures (about 60°C to 100°C) or those containing an irreversible gelling agent which is prepared by cross-linking a gelling agent; that is, the jelly itself is not intraorally dissolved but easily dispersed by physical force upon swallowing.
• these conventional jelly formulations require heating at high temperatures upon preparation or contain a metal salt as a cross-linking agent, so that poor stability thereof may be a problem particularly in the case that the formulations contain drugs having poor heat stability or proteins or peptides strongly interacting with metal salts.
• formulations in film shape are also known in which a drug is dispersed or dissolved in a water-soluble polymer.
• Such conventional formulations in film shape require a certain quantity of saliva for intraorally dissolving or swelling them using water-soluble polymers.
• some dysphagia patients may take a long period to dissolve the formulations.
• the film-form preparations easily absorb water; thus, disadvantageously, they easily stick to the oral mucous membrane and cause discomfort.
• the solubility and the thickness and size of the film are correlative to each other. As a result, it is difficult to prepare a film containing a drug as much as more than 100 mg.
• the Patent Documents disclose that such formulations in film shape may be prepared by dissolving a water-soluble polymer in water as a solvent, dissolving a drug thereinto, and heat-drying it. Particularly in the case of drugs that are vulnerable to heat, however, a decrease in the drug content due to heat is a concern. If the drug is in a liquid form, the sheet-form formulation may be disadvantageously dissolved, so that keeping of a given shape may be difficult.
• the present invention aims to provide a sheet-form preparation that can be easily dissolved intraorally, that can allow the dissolution time thereof to be easily controlled, and that can stably contain a drug except an allergenic protein from cedar pollen; and a method for producing the sheet-form preparation.
• a sheet-form preparation having physical properties without problems in use can be prepared if the preparation contains, as the base material, gelatin that gels at ordinary temperature and maintains an individual state, that easily dissolves at a temperature close to the body temperature, and that contributes to the stabilization of a drug that is vulnerable to heat, and contains, if necessary, sugars, sugar alcohols, polyethylene glycol, crystalline cellulose, and the like.
• a sheet-form preparation has preparation characteristics suitable for intraoral drug administration including sublingual administration. Thereby, the present inventors have completed the present invention.
• the present invention relates to a sheet-form preparation comprising: water; gelatin; and a drug except an allergenic protein from cedar pollen.
• the sheet-form preparation of the present invention preferably further comprises at least one selected from the group consisting of sugars, sugar alcohols, and sugar fatty acids.
• the sheet-form preparation of the present invention preferably further comprises polyethylene glycol or a derivative thereof, and also preferably further comprises crystalline cellulose.
• the drug except an allergenic protein from cedar pollen is preferably provided in a liquid or solid form containing this drug.
• the amount of the gelatin is preferably 2 to 40 wt% based on the total weight.
• the sheet-form preparation of the present invention preferably has a thickness within the range of 30 to 5000 ⁇ m, and also preferably has a planar surface area within the range of 0.5 to 6.0 cm 2 .
• the present invention also relates to a method for producing the sheet-form preparation of the present invention. The method comprises the steps of: preparing a mixed solution by mixing water, gelatin, and a drug except an allergenic protein from cedar pollen; and forming a thin film using the mixed solution.
• a water content in the obtained sheet-form preparation is adjusted by adjusting the amount of water to be added in the step of preparing a mixed solution or by drying the thin film after the step of forming a thin film.
• the sheet-form preparation of the present invention contains water, gelatin, and a drug except an allergenic protein from cedar pollen.
• the sheet-form preparation of the present invention having such a composition is used adequately for intraoral hyposensitization therapy, which requires control of sensitized time, and is particularly suited for sublingual hyposensitization therapy.
• the sheet-form preparation of the present invention contains gelatin and a specific stabilizing agent, the drug except an allergenic protein from cedar pollen, especially proteins and peptides, can be stably maintained.
• the thickness of the sheet-form preparation of the present invention is not particularly limited, and it is preferably 30 to 5,000 ⁇ m.
• a film having a thickness of less than 30 ⁇ m may suffer problems in sheet strength and product handleability, while a film having a thickness of higher than 5,000 ⁇ m may cause discomfort when intraorally, in particular, sublingually, administered.
• the size of the sheet-form preparation of the present invention is not particularly limited, and it is preferable that the planar surface area is within the range of 0.5 to 6.0 cm 2 .
• a film having a surface area of less than 0.5 cm 2 may cause difficulty in handling when pinch-administering the sheet-form preparation, while a film having a surface area of higher than 6.0 cm 2 may not be perfectly inserted intraorally, in particular, sublingually.
• the planar shape of the sheet-form preparation of the present invention is not particularly limited. Examples thereof include rectangles such as oblongs and squares, polygons such as pentagons, circles, ellipses, and the like. Polygons referred to herein include, in addition to complete polygons, shapes having a slight curve in an angular portion.
• sheet-form herein is a concept that includes "film-form".
• the sheet-form preparation of the present invention contains gelatin.
• the gelatin is an ingredient that constitutes the base material of the sheet-form preparation of the present invention, and has a film-forming ability and edibility.
• the sheet-form preparation of the present invention gels at ordinary temperature and can be dissolved easily at a temperature close to the intraoral body temperature. Further, gelatin can gel at the lowest temperatures among thermoreversible gelling agents. Thus, preparations can be produced at around ordinary temperature to 40°C, so that the stability of drugs having low heat stability can be maintained during production.
• the term "edibility" herein means that the gelatin is orally administrable and is pharmaceutically acceptable.
• the gelatin is preferably in a grade referred to as water-soluble gelatin which is soluble in water at ordinary temperature.
• water-soluble gelatin a grade referred to as water-soluble gelatin which is soluble in water at ordinary temperature.
• water-soluble gelatin enables to prepare the sheet-form preparation of the present invention at near ordinary temperature and to secure stability of the drug described below during production.
• the term "water-soluble gelatin” herein indicates a gelatin such that 1 g of gelatin dissolves in 20 mL of water at ordinary temperature (30°C).
• the gelatin preferably has a characteristic such that it does not gel at 32°C but gels at 5°C when turned into an aqueous solution at a concentration of 10 wt%. This is because some gelatins having such a characteristic may sufficiently provide the effects of the present invention depending on the molecular weight thereof and the amount of hydroxyproline therein even if they are beyond the grade of water-soluble gelatins.
• gelatin used in the sheet-form preparation of the present invention examples include those prepared by enzymatically decomposing and extracting proteins contained in animal skin or bone, such as those obtained by acid-treating or alkali-treating proteins derived from pigs, cattle, and fish.
• the above-mentioned gelatin is particularly preferably a gelatin derived from fish or pigs from the viewpoints of its producibility at ordinary temperature during production and stability of the drug which is vulnerable to heat during production. From such viewpoints, any gelatin may be adequate as long as it contains hydroxyproline in the amino acid composition in an amount of 5.2 to 9.2 mol% and it has an average molecular weight of exceeding 90,000.
• gelatin examples include those derived from fishes such as a salmon-derived gelatin (hydroxyproline amount in amino acid composition: 5.4 mol%), carp-derived gelatin (hydroxyproline amount in amino acid composition: 7.6 mol%), and tilapia-derived gelatin (hydroxyproline amount in amino acid composition: 8.0 mol%). Particularly preferable is a tilapia-derived gelatin.
• the above-mentioned amino acid composition is obtained by analysis wherein gelatin is hydrolyzed, then separated by ion-exchange chromatography, and detected by ninhydrin.
• Specific examples of the amount of hydroxyproline in the amino acid composition (mol%) obtained by the above-described method are as follows. Fowl: 10.8 mol% Ostrich: 10.4 mol% Mouse: 8.7 mol% Pig: 9.4 mol% Cattle: 9.5 mol%
• any gelatin may be preferable regardless of the amount of hydroxyproline in the amino acid composition as long as it has an average molecular weight of 50,000 to 90,000.
• the term "average molecular weight” herein means a weight average molecular weight measured by gel-filtration chromatography analysis. Further, the average molecular weight herein means a molecular weight of each polypeptide chain monomer, not the molecular weight of the polypeptide chain trimer, of gelatin.
• the amount of the gelatin is preferably 2 to 40 wt%, and more preferably 3 to 30 wt%, based on the total weight of the sheet-form preparation of the present invention. If the amount is less than 2 wt%, the gelatin may not gel at ordinary temperature. On the other hand, if the amount is in excess of 40 wt%, the intraoral solubility of the sheet-form preparation of the present invention is extremely low, which may cause a problem during use.
• the sheet-form preparation of the present invention may also contain a suitable amount of an edible polymer that is soluble only in water or an edible polymer that dissolves neither in water nor in an organic solvent (hereafter, these are also collectively referred to as other edible polymers) in combination, to the extent that they do not inhibit the effects of the present invention.
• Examples of the other edible polymers include synthetic macromolecular compounds such as polyethylene glycol, polyvinyl alcohol, carboxyvinyl polymer, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose with a low substitution degree, crystalline cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, and sodium carboxymethyl starch; and macromolecular compounds obtained from natural products such as dextran, casein, guar gum, xanthan gum, tragacanth gum, acacia gum, gum arabic, gellan gum, and starch. Each of these other edible polymers can be used alone or two or more of these can be used in combination.
• the amount of the other edible polymers is preferably 0.1 to 10 wt% based on the total weight of the sheet-form preparation of the present invention.
• the sheet-form preparation of the present invention contains a drug except an allergenic protein from cedar pollen.
• the drug except an allergenic protein from cedar pollen is not particularly limited, and is preferably a drug which can be administered to mammals, such as human, sublingually, intraorally, or through the intestinal tract, that is, can be orally administered.
• Such a drug include general anesthetics, sedative hypnotics, antiepileptic drugs, antipyretic-analgesic-antiinflammatory drugs, anti-vertiginous drugs, psychoneurotic drugs, central-nervous-system drugs, antidementia drugs, local anesthetics, skeletal muscle relaxants, autonomic-nervous-system drugs, antispasmodics, antiparkinson drugs, antihistamines, cardiotonics, antiarrhythmic drugs, diuretics, hypotensive agents, vasoconstrictors, coronary vasodilators, peripheral vasodilators, antiarteriosclerotic drugs, circulatory-system drugs, respiratory stimulants, cough suppressants and expectorants, hormone drugs, external preparations for purulent diseases, analgesic-antipruritic-astringent-antiphlogistic drugs, drugs for parasitic skin diseases, hemostatics, gout remedies, antidiabetic drugs, antineoplastics, antibiotics, chemotherapeutic
• the above drugs each may be used in an amount enough to cause desired results, such as therapeutic results, through treatment for diseases, conditions, or disorders, that is, in an amount also called an effective dose herein.
• the effective dose of a drug means that the drug is used in an amount which does not cause toxicity but is sufficient to show the selected effect for a specific period, for example. Such an amount can be easily determined by the skilled person of the technical field of the present invention based on the conventional techniques.
• the allergenic protein from cedar pollen is typically included in a cedar pollen extract. In one embodiment of the present invention, the drug can exclude the cedar pollen extract.
• the drug except an allergenic protein from cedar pollen may be a solid drug or a liquid drug.
• the solid drug herein means a drug which is in a solid state at room temperature (25°C), in other words, a drug having a melting point of higher than 25°C.
• the melting point herein is a value determined using a DSC, type DSC6220 (Seiko Instruments Inc. (SII)).
• the liquid drug except an allergenic protein from cedar pollen is a drug having fluidity at room temperature, or 25°C, in other words, having a viscosity of 0.05 to 100,000 mPa ⁇ s.
• the viscosity of the drug is measured using an E-type viscometer while the drug is kept at 25°C.
• the amount of the drug except an allergenic protein from cedar pollen depends on the properties and the like thereof. In general, the amount is preferably 1 x 10 -10 to 80 wt% to the total weight of the sheet-form preparation of the present invention. If the amount is less than 1 x 10 -10 wt%, many drugs may not show their efficacy from the viewpoint of clinical effects. If the amount is in excess of 80 wt%, the strength of the sheet-form preparation of the present invention may be reduced noticeably, likely causing problems in the ability to maintain the shape.
• the amount of the drug except an allergenic protein from cedar pollen is more preferably in the range of 1 x 10 -6 to 50 wt%. An amount in this range probably leads to preparation of preparations without problems during production and in practice.
• the sheet-form preparation of the present invention contains water.
• the water is an ingredient that has an effect of assisting dissolution of the sheet-form preparation.
• controlling of the water content in the sheet-form preparation of the present invention enables to easily control the dissolution time of the sheet-form preparation. Consequently, the sheet-form preparation of the present invention is appropriate for both cases of intraorally dissolving and taking the drug or of intraorally, in particular, sublingually, slowly dissolving and control-releasing the drug.
• the water content is preferably 1 to 60 wt%, and more preferably 5 to 50 wt%, based on the total weight of the sheet-form preparation.
• the intraorally solubility may be extremely poor, which may cause a problem during use.
• the water content is in excess of 60 wt%, the storage stability at ordinary temperature regarding physical properties may be poor.
• the sheet-form preparation of the present invention preferably further comprises an additive which improves physical properties and solubility, such as at least one selected from the group consisting of sugars, sugar alcohols, and sugar fatty acids.
• an additive which improves physical properties and solubility, such as at least one selected from the group consisting of sugars, sugar alcohols, and sugar fatty acids.
• sugars include monosaccharides, disaccharides, and tri- to hexa-saccharides as indicated below.
• Examples of the monosaccharides include aldotetroses such as erythrose and threose, aldopentoses such as ribose, lyxose, xylose, and arabinose, aldohexoses such as allose, talose, gulose, glucose, altrose, mannose, galactose, and idose, ketotetroses such as erythrulose, ketopentoses such as xylulose and ribulose, ketohexoses such as psicose, fructose, sorbose, and tagatose.
• aldotetroses such as erythrose and threose
• aldopentoses such as ribose, lyxose, xylose, and arabinose
• aldohexoses such as allose, talose, gulose, glucose, altrose, mannose, galactose, and i
• disaccharides examples include ⁇ -diglucosides such as trehalose, kojibiose, nigerose, maltose, and isomaltose, ⁇ -diglucosides such as isotrehalose, sophorose, laminaribiose, cellobiose, and genthiobiose, and ⁇ , ⁇ -diglucosides such as neotrehalose, as well as lactose, sucrose, and isomaltulose (Palatinose).
• examples of the trisaccharides include raffinose.
• tri- to hexa-saccharide oligosaccharides examples include fructooligosaccharide, galactooligosaccharide, xylooligosaccharide, isomaltooligosaccharide, chitin oligosaccharide, chitosan oligosaccharide, oligoglucosamine, dextrin, and cyclic oligosaccharides such as cyclodextrin.
• alcohols of the monosaccharides include tetritols such as erythritol, D-threitol, and L-threitol, pentitols such as D-arabinitol and xylitol, hexitols such as D-iditol, galactitol (dulcitol), D-glucitol (sorbitol), and mannitol, and cyclitols such as inositol.
• examples of alcohols of the disaccharides include maltitol, lactitol, and reduced palatinose (isomalt).
• oligosaccharides include pentaerythritol and reduced maltose syrup.
• the sugars or sugar alcohols may be substituted. Further, each of these may be used alone or two or more of these may be used in combination.
• the sugars or sugar alcohols are preferably mono- to tri-saccharides or sugar alcohols thereof.
• sugar fatty acids examples include sorbitan fatty acid esters and sucrose fatty acid esters.
• examples of the sorbitan fatty acid esters include sorbitan monooleate, sorbitan trioleate, sorbitan sesquioleate, sorbitan cocoate, and polyoxyethylene sorbitan fatty acid esters.
• examples of the sucrose fatty acid esters include sucrose stearate, sucrose oleate, sucrose palmitate, sucrose myristate, sucrose behenate, sucrose erucate, and sucrose-mixed fatty acid esters. These sugar fatty acids are useful as an antifoaming agent, as well as stabilizing agents for proteins and peptides; thus, they are very convenient.
• the sheet-form preparation of the present invention preferably contains polyethylene glycol or a derivative thereof and cellulose as additives for improving the physical properties.
• the polyethylene glycol preferably has an average molecular weight of 200 to 20,000, and more preferably an average molecular weight of 400 to 8,000. If the average molecular weight is 200 or lower, the additives may have high plasticity, so that sufficient physical properties required for use may not be achieved. If the average molecular weight is in excess of 20,000, the preparation may have high viscosity upon dissolution, so that it may cause discomfort in the mouth cavity.
• the average molecular weight herein is determined by the average molecular weight test described in the item of Macrogol 400 in the official monographs of the Japanese Pharmacopoeia 15th edition.
• the cellulose is preferably crystalline cellulose or powder cellulose, and more preferably crystalline cellulose.
• the cellulose preferably has an average particle size of 0.01 to 100 ⁇ m. It more preferably has an average particle size of 0.01 to 50 ⁇ m. If the average particle size is smaller than 0.01 ⁇ m, the particles are likely to aggregate in the solution during preparation, and they may adversely deteriorate the physical properties. If the average particle size is larger than 100 ⁇ m, the particles are likely to precipitate in the solution during preparation and they may cause sense of residues and discomfort when the preparation is intraorally administered.
• the average particle size herein is a 50% average particle size determined using a laser scattering particle size distribution measurement device.
• the amount of the additives is preferably 1 to 80 wt%, and more preferably 5 to 70 wt%, based on the total weight of the sheet-form preparation of the present invention. If the amount is less than 1 wt%, the physical properties may not be sufficiently maintained during use. On the other hand, if the amount is in excess of 80 wt%, it may be difficult to control the physical properties of the sheet-form preparation by the added additives.
• the sheet-form preparation of the present invention may appropriately contain, as ingredients constituting the base material, a perfume, a flavoring substance, a sweetening agent, a colorant, an antiseptic, an antioxidant, a stabilizing agent, a surfactant, and the like, in addition to the ingredients mentioned above.
• these ingredients are not particularly limited and conventionally known ones may be used.
• the sheet-form preparation of the present invention contains gelatin as mentioned above, it gels at ordinary temperature and can be easily intraorally dissolved at a temperature close to the body temperature. Further, if the formulation contains gelatin and a specific additive, the physical properties during use can be significantly improved. Furthermore, the drug except an allergenic protein from cedar pollen, especially proteins and peptides, can be stably maintained. In addition, since the dissolution time of the sheet-form preparation of the present invention can be easily controlled by controlling the water content therein, it is suited for intraoral, in particular, sublingual, hyposensitization therapy, which requires control of the sensitization time. The sheet-form preparation of the present invention may be directly swallowed of course, or may be intraorally dissolved immediately and then swallowed.
• absorption of the drug through the oral mucous membrane or sublingual mucous membrane can be expected by adjusting the intraoral dissolution time. Since the preparation can be wholly dissolved at a temperature close to the body temperature so that it causes no sense of residues, and since the preparation has a sheet shape so that its surface area is larger than that of tablets or the like and patients and caregivers can easily pinch it, the QOL of the patients and caregivers can be greatly improved.
• the sheet-form preparation of the present invention can be produced by, for instance, a method having the steps of: preparing a mixed solution by mixing water, gelatin, and a drug except an allergenic protein from cedar pollen; and forming a thin film using the mixed solution, wherein the water content in the obtained sheet-form preparation is adjusted by adjusting the amount of water to be added in the step of preparing a mixed solution or by drying the thin film after the step of forming the thin film.
• a method for producing the sheet-form preparation of the present invention is also one aspect of the present invention.
• gelatin and other additives are first dissolved in a predetermined amount of water at ordinary temperature or under heating, and additives that do not dissolve are dispersed homogeneously to prepare a gelatin solution. If the drug is thermally stable, the drug may be added in this step. In contrast, if thermally unstable, the drug is added after the gelatin solution is cooled down to about ordinary temperature to 35°C, and then stir-mixed. If foaming occurs during the preparation of a mixed solution, it is adequate to leave the solution overnight or to perform vacuum or reduced pressure degassing.
• a predetermined amount of the mixed solution is dispensed into a plastic blister case of a desired size at a temperature of 28°C to 32°C, and cool-solidified immediately after the dispensation to form the thin film.
• a suitable amount of the mixed solution may be spread over a release film and cool-solidified to form the thin film, and then the film may be cut into a desired size.
• the thin film formed in the present step preferably has a size equal to the sheet-form preparation of the present invention descried above.
• the water content in the obtained sheet-form preparation is adjusted by adjusting the amount of water to be added in the step of preparing a mixed solution or by drying the thin film after the step of forming a thin film. That is, in the case of adjusting the water content in the step of preparing a mixed solution by adjusting the amount of water to be added, the sheet-form preparation of the present invention can be produced by forming the thin film described above. Meanwhile, in the case of adjusting the water content after the step of forming a thin film by drying the thin film, the sheet-form preparation of the present invention can be produced by drying the thin film described above. Examples of the method for drying the thin film include a method comprising a cold air drying step or a reduced pressure cool drying step.
• the method for producing the sheet-form preparation of the present invention is extremely useful in that, for example, the film can be prepared at low temperatures of 35°C or lower, preferably 30°C or lower, with respect to drugs having extremely low thermal stability.
• the obtained sheet-form preparation is preferably seal-packaged if necessary and treated as a product.
• the sheet-form preparation of the present invention contains gelatin, it gels at ordinary temperature and can be easily intraorally dissolved at a temperature close to the body temperature.
• the dissolution time of the film can be easily controlled by controlling the water content thereof, the sheet-form preparation of the present invention is suited for intraoral, in particular, sublingual, hyposensitization therapy, which requires control of the sensitization time.
• the sheet-form preparation of the present invention contains gelatin and a specific additive, the physical properties during use can be significantly improved.
• the preparation can stably maintain the drug except an allergenic protein from cedar pollen, especially proteins and peptides.
• the sheet-form preparation of the present invention may be directly swallowed, or may be immediately intraorally dissolved and then be swallowed. Furthermore, absorption of the drug through the oral mucous membrane or sublingual mucous membrane can be expected by adjusting the intraoral dissolution time. Since the preparation can be wholly dissolved at a temperature close to the body temperature so that it causes no sense of residues, and since the preparation has a sheet shape so that its surface area is larger than that of tablets or the like and patients and caregivers can easily pinch it, the QOL of the patients and caregivers can be greatly improved. Moreover, the gelatin used in the method for producing the sheet-form preparation of the present invention is one which can be used even in the preparation at lower temperature in comparison with conventional thermoreversible gelling agents. Thus, the sheet-form preparation can be produced while reducing content loss of thermally unstable drugs upon preparation thereof.
• Sheet-form preparations were obtained in the same manner as in Example 2 except that the compositions were those indicated in Table 1.
• gelatin A pig-derived
• alkaline-treated gelatin A pig-derived
• acid-treated gelatin pig-derived
• gelatin B pig-derived
• gelatin cattle-derived
• Sheet-form preparations were obtained in the same manner as in Comparative Example 1 except that the compositions were those indicated in Table 1.
• Sheet-form preparations were obtained in the same manner as in Example 8 except that the compositions were those indicated in Table 2.
• Sheet-form preparations were obtained in the same manner as in Example 15 except that the compositions were those indicated in Table 3.
• Sheet-form preparations were obtained in the same manner as in Example 21 except that the compositions were those indicated in Table 4.
• Example 22 crystalline cellulose C (average particle size: 90 ⁇ m) was used; in Example 23, powder cellulose A (average particle size: 6 ⁇ m) was used; in Example 24, powder cellulose B (average particle size: 10 ⁇ m) was used; and in Example 25, powder cellulose C (average particle size: 50 ⁇ m) was used.
• Sheet-form preparations were obtained in the same manner as in Example 1 except that the compositions were those indicated in Table 5. Part of the purified water in the respective sheet-form preparations in Examples 1 to 29 was replaced with the equivalence of a drug except an allergenic protein from cedar pollen. Thereby, sheet-form preparations containing the drug were obtained.
• This mixture was heated to reach 25°C to 30°C and the whole was added to the gelatin solution prepared beforehand, and they were immediately mixed at 28°C to 32°C.
• the mixture was dispensed into 5-cm 2 plastic blister cases (Cryomold (square type) No. 3, Sakura Finetek Japan Co., Ltd.) in 2-g portions, and the portions were cool-solidified at 2°C to 8°C for one day and one night. Thereby, sheet-form preparations were obtained.
• crystalline cellulose A average particle size: 20 ⁇ m
• the cellulose was ultrasound-dissolved and dispersed therein.
• 20 parts by weight of fish (tilapia)-derived water-soluble gelatin was added thereto and dissolved therein at 30°C to 50°C, and shaken in a shaker under a constant temperature of 30°C to 35°C to prepare a gelatin solution.
• 0.2 parts by weight of mite antigen DerfI, 10 parts by weight of D-sorbitol, and 5 parts by weight of PEG 4000 were added thereto and immediately mix-dissolved therein at 28°C to 32°C.
• the mixture was dispensed into 1-cm 2 plastic blister cases (Cryomold (square type) No. 1, Sakura Finetek Japan Co., Ltd.) in 0.5-g portions, and the portions were cool-solidified at 2°C to 8°C for one day and one night. Thereby, sheet-form preparations were obtained.
• Sheet-form preparations were obtained in the same manner as in Example 32 except that the compositions were those indicated in Table 6.
• the sheet-form preparations prepared in the respective examples and comparative examples were evaluated on intraoral solubility, gelling temperature during preparation, sensory test (touch), and storage stability at 25°C storage (the sensory test (touch)). Some of the samples were further measured for intraoral dissolution time, intraoral sensory test (roughness), and melting point. The following describes the respective test methods, and Tables 7 to 9 show the results.
• the test was carried out according to the disintegration test described in the Japanese Pharmacopoeia 15th edition. Distilled water was introduced in a 1000-mL low-form beaker, and the test was carried out at 37 ⁇ 2°C, under conditions where the test container was raised and lowered 29 to 32 times with an amplitude of 53 to 57 mm in one minute. A sheet-form preparation was introduced in the test container, and the test was started under the conditions described above. The time from the beginning of the test to when the sheet-form preparation was completely dissolved and disappeared from the test container was taken as the intraoral dissolution time.
• a 1000-mL glass Petri dish was charged with 900 mL of phosphate buffer with a pH of 6.8.
• a stainless-steel sieve ( ⁇ 4 mm) was submerged therein upside down, and the solution was stirred using a stirrer (300 rpm).
• the temperature of this solution was controlled to 37 ⁇ 2°C with a constant temperature water circulator, and a test specimen (5 cm 2 ) was submerged therein. The specimen was left for 10 minutes from the time of submerging the specimen, and whether the specimen was left on the stainless-steel sieve was observed. The evaluation was performed based on the following criteria.
• the prepared sheet-form preparations were stored in a thermostatic chamber set to 25°C.
• the sheet-form preparations were taken out one month after the beginning of the storage, and the sensory test (touch) was carried out.
• the evaluation method was according to the sensory test (touch).
• the preparation was actually administered to two subjects, and the subjects dissolved the preparation on the tongue, and evaluated roughness at this time.
• the evaluation criteria were as follows:
• the sheet-form preparation of the present invention contains gelatin, it gels at ordinary temperature and can be easily dissolved at a temperature close to the intraoral body temperature.
• the dissolution time of the film can be easily controlled by controlling the water content thereof, the sheet-form preparation of the present invention is suited for intraoral, in particular sublingual, hyposensitization therapy, which requires control of the sensitization time.
• the sheet-form preparation of the present invention contains gelatin and a specific additive, the physical properties during use can be significantly improved.
• the preparation can stably maintain the drug except an allergenic protein from cedar pollen, especially proteins and peptides.
• the sheet-form preparation of the present invention may be directly swallowed, or may be immediately intraorally dissolved and swallowed.
• absorption of the drug through the oral mucous membrane or sublingual mucous membrane can be expected by adjusting the intraoral dissolution time. Since the preparation can be wholly dissolved at a temperature close to the body temperature so that it causes no sense of residues, and since the preparation has a sheet shape so that its surface area is larger than that of tablets or the like and patients and caregivers can easily pinch it, the QOL of the patients and caregivers can be greatly improved. Moreover, in the method for producing the sheet-form preparation of the present invention, gelatin to be used can be stable even in preparation at lower temperatures in comparison with conventional tharmoreversible gelling agents. Thus, the sheet-form preparation can be produced while reducing content loss of thermally unstable drugs upon preparation thereof.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Zoology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Inorganic Chemistry (AREA)
• Biomedical Technology (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Pulmonology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Applications Claiming Priority (1)

Publications (1)

Family

ID=45350603

Family Applications (1)

Country Status (7)

Cited By (1)

Families Citing this family (1)

Citations (5)

Family Cites Families (11)

• 2010
  • 2010-12-10 JP JP2010276190A patent/JP5555148B2/ja not_active Expired - Fee Related
• 2011
  • 2011-12-08 RU RU2011150078/02A patent/RU2011150078A/ru unknown
  • 2011-12-08 CA CA2761404A patent/CA2761404A1/en not_active Abandoned
  • 2011-12-08 US US13/314,662 patent/US20120148656A1/en not_active Abandoned
  • 2011-12-08 EP EP11009696A patent/EP2462928A1/en not_active Withdrawn
  • 2011-12-08 KR KR1020110130908A patent/KR20120065247A/ko not_active Application Discontinuation
  • 2011-12-08 CN CN2011104063222A patent/CN102552219A/zh active Pending

Patent Citations (7)

Also Published As

Similar Documents

Legal Events